FI114156B - Menetelmä tetratsolijohdannaisen valmistamiseksi kahtena kidemuotona ja mainitun johdannaisen uusi kidemuoto - Google Patents
Menetelmä tetratsolijohdannaisen valmistamiseksi kahtena kidemuotona ja mainitun johdannaisen uusi kidemuoto Download PDFInfo
- Publication number
- FI114156B FI114156B FI954992A FI954992A FI114156B FI 114156 B FI114156 B FI 114156B FI 954992 A FI954992 A FI 954992A FI 954992 A FI954992 A FI 954992A FI 114156 B FI114156 B FI 114156B
- Authority
- FI
- Finland
- Prior art keywords
- butyl
- methyl
- tetrazol
- biphenyl
- diazaspiro
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title description 14
- 150000003536 tetrazoles Chemical class 0.000 title description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 48
- 239000002904 solvent Substances 0.000 claims abstract description 25
- 238000002441 X-ray diffraction Methods 0.000 claims abstract description 13
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 claims abstract description 12
- YOSHYTLCDANDAN-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2NN=NN=2)C(CCCC)=NC21CCCC2 YOSHYTLCDANDAN-UHFFFAOYSA-N 0.000 claims abstract description 9
- 150000001540 azides Chemical class 0.000 claims abstract description 7
- KWEQEHOPDHARIA-UHFFFAOYSA-N 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]phenyl]benzonitrile Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C#N)C(CCCC)=NC21CCCC2 KWEQEHOPDHARIA-UHFFFAOYSA-N 0.000 claims abstract description 6
- 159000000011 group IA salts Chemical class 0.000 claims abstract description 3
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 66
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 57
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims description 55
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- WDBHYTAEQAWRCQ-UHFFFAOYSA-N 1-nonen-4-one Chemical compound CCCCCC(=O)CC=C WDBHYTAEQAWRCQ-UHFFFAOYSA-N 0.000 claims description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 23
- 239000000047 product Substances 0.000 claims description 22
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 20
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 16
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 13
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 claims description 9
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 claims description 9
- 238000002844 melting Methods 0.000 claims description 8
- 230000008018 melting Effects 0.000 claims description 8
- 150000001447 alkali salts Chemical class 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000002955 isolation Methods 0.000 claims description 4
- 238000002835 absorbance Methods 0.000 claims description 3
- 239000012043 crude product Substances 0.000 claims description 3
- 239000003880 polar aprotic solvent Substances 0.000 claims description 3
- 239000012736 aqueous medium Substances 0.000 claims description 2
- XZFUGEODKDDZQP-UHFFFAOYSA-N spiro[4.4]non-1-en-4-one Chemical group O=C1CC=CC11CCCC1 XZFUGEODKDDZQP-UHFFFAOYSA-N 0.000 claims description 2
- ULWZXKQYQLRMNW-UHFFFAOYSA-N CCCCN1N=C(N=N1)C2=CC=CC=C2C3=CC=C(C=C3)CN4C=NC5(C4=O)CCCC5 Chemical compound CCCCN1N=C(N=N1)C2=CC=CC=C2C3=CC=C(C=C3)CN4C=NC5(C4=O)CCCC5 ULWZXKQYQLRMNW-UHFFFAOYSA-N 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000000010 aprotic solvent Substances 0.000 abstract 1
- 239000013078 crystal Substances 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 150000002825 nitriles Chemical class 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- -1 2-n-butyl Chemical group 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 238000001953 recrystallisation Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 3
- 238000002447 crystallographic data Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- VMQLILGAYAPXKA-UHFFFAOYSA-N 1,3-diazaspiro[4.4]non-1-en-4-one Chemical compound O=C1NC=NC11CCCC1 VMQLILGAYAPXKA-UHFFFAOYSA-N 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N 1-nonene Chemical compound CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- IBQLOWPHNGLCNT-UHFFFAOYSA-N 2-butyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-ene Chemical compound C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C2=NNN=N2)C(CCCC)=NC21CCCC2 IBQLOWPHNGLCNT-UHFFFAOYSA-N 0.000 description 2
- CAAMSDWKXXPUJR-UHFFFAOYSA-N 3,5-dihydro-4H-imidazol-4-one Chemical compound O=C1CNC=N1 CAAMSDWKXXPUJR-UHFFFAOYSA-N 0.000 description 2
- IJIBRSFAXRFPPN-UHFFFAOYSA-N 5-bromo-2-methoxybenzaldehyde Chemical compound COC1=CC=C(Br)C=C1C=O IJIBRSFAXRFPPN-UHFFFAOYSA-N 0.000 description 2
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 2
- 239000002083 C09CA01 - Losartan Substances 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
- 229960004773 losartan Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- MGGVALXERJRIRO-UHFFFAOYSA-N 4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-2-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-1H-pyrazol-5-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)O MGGVALXERJRIRO-UHFFFAOYSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GIRNCFBNEDMYLC-UHFFFAOYSA-N [2-butyl-5-chloro-3-[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]imidazol-4-yl]methanol Chemical compound CCCCC1=NC(Cl)=C(CO)N1C1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 GIRNCFBNEDMYLC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012866 crystallographic experiment Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000004562 water dispersible granule Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Photoreceptors In Electrophotography (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9412459A FR2725987B1 (fr) | 1994-10-19 | 1994-10-19 | Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive |
| FR9412459 | 1994-10-19 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI954992A0 FI954992A0 (fi) | 1995-10-19 |
| FI954992L FI954992L (fi) | 1996-04-20 |
| FI114156B true FI114156B (fi) | 2004-08-31 |
Family
ID=9467986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI954992A FI114156B (fi) | 1994-10-19 | 1995-10-19 | Menetelmä tetratsolijohdannaisen valmistamiseksi kahtena kidemuotona ja mainitun johdannaisen uusi kidemuoto |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US5629331A (cs) |
| EP (1) | EP0708103B1 (cs) |
| JP (1) | JP3366786B2 (cs) |
| KR (1) | KR100251222B1 (cs) |
| CN (1) | CN1061656C (cs) |
| AT (1) | ATE198478T1 (cs) |
| AU (1) | AU698041B2 (cs) |
| CA (1) | CA2160725C (cs) |
| CY (1) | CY2277B1 (cs) |
| CZ (2) | CZ288629B6 (cs) |
| DE (1) | DE69519788T2 (cs) |
| DK (1) | DK0708103T3 (cs) |
| ES (1) | ES2155115T3 (cs) |
| FI (1) | FI114156B (cs) |
| FR (1) | FR2725987B1 (cs) |
| GR (1) | GR3035503T3 (cs) |
| HU (1) | HU226461B1 (cs) |
| IL (1) | IL115688A (cs) |
| NO (1) | NO307516B1 (cs) |
| NZ (1) | NZ280293A (cs) |
| PL (1) | PL184193B1 (cs) |
| PT (1) | PT708103E (cs) |
| RU (1) | RU2144536C1 (cs) |
| SI (1) | SI0708103T1 (cs) |
| TW (1) | TW357147B (cs) |
| ZA (1) | ZA958850B (cs) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW442301B (en) * | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
| US5994348A (en) * | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
| FR2780403B3 (fr) | 1998-06-24 | 2000-07-21 | Sanofi Sa | Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant |
| DE69940063D1 (de) | 1998-07-06 | 2009-01-22 | Bristol Myers Squibb Co | Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin |
| PL205715B1 (pl) * | 2000-07-19 | 2010-05-31 | Novartis Ag | Sól wapniowa walsartanu w postaci tetrahydratu, preparat farmaceutyczny zawierający tę sól, zastosowanie i sposób wytwarzania tej soli |
| EP1453826A1 (en) * | 2001-12-10 | 2004-09-08 | Dr. Reddy's Laboratories Ltd. | Amorphous form of 2-n-butyl-3-[[2-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4,4'] non-1-en-4-one |
| ES2273041T3 (es) * | 2002-07-16 | 2007-05-01 | Teva Pharmaceutical Industries Ltd. | Nueva sintesis de irbesartan. |
| EP2189457A1 (en) * | 2003-01-16 | 2010-05-26 | Teva Pharmaceutical Industries Ltd. | Novel synthesis of irbesartan |
| PT1590343E (pt) * | 2003-02-05 | 2008-09-11 | Teva Pharma | Síntese de 2-butil-3-(2¿-(1-tritil-1h-tetrazol-5-il)bifenil-4-il)-1,3-diazaspiro-4,4-non-en-4-ona |
| AU2003242984A1 (en) * | 2003-04-07 | 2004-11-01 | Hetero Drugs Limited | A novel crystalline form of irbesartan |
| PL379420A1 (pl) * | 2003-07-31 | 2006-09-04 | Nicox S.A. | Pochodne blokerów receptora angiotensyny II |
| TW200526638A (en) * | 2003-10-22 | 2005-08-16 | Smithkline Beecham Corp | 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline |
| WO2005051943A1 (en) * | 2003-11-28 | 2005-06-09 | Ranbaxy Laboratories Limited | Processes for the preparation of highly pure irbesartan |
| DE602005025755D1 (de) | 2004-06-04 | 2011-02-17 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
| WO2006001026A1 (en) * | 2004-06-23 | 2006-01-05 | Hetero Drugs Limited | Irbesartan polymorphs |
| SI21849A (sl) * | 2004-07-29 | 2006-02-28 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Priprava hidrokloridnih soli tetrazolskega derivata |
| TWI346108B (en) | 2004-08-23 | 2011-08-01 | Bristol Myers Squibb Co | A method for preparing irbesartan and intermediates thereof |
| GB2419592A (en) * | 2004-10-26 | 2006-05-03 | Cipla Ltd | Process for the preparation of irbesartan hydrochloride |
| ES2454197T3 (es) | 2004-11-11 | 2014-04-09 | Lek Pharmaceuticals D.D. | Formas polimórficas de Irbesartán |
| ES2259909B1 (es) * | 2005-02-28 | 2007-06-16 | Inke, S.A. | Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de su intermedio de sintesis. |
| WO2007013101A1 (en) * | 2005-07-27 | 2007-02-01 | Jubilant Organosys Limited | PROCESS FOR PRODUCING 2-(N-BUTYL)-3-[[2'-(TETRAZOL-5-YL)BIPHENYL- 4-YL]METHYL]-l,3-DIAZASPIRO[4.4] NON-1-EN-4-ONE |
| PL1806130T3 (pl) | 2006-01-09 | 2010-08-31 | Krka D D Novo Mesto | Kompozycja farmaceutyczna w postaci stałej zawierająca irbesartan |
| WO2008041957A1 (en) * | 2006-10-03 | 2008-04-10 | Ulkar Kimya Sanayi Ve Ticaret As | Method for producing pure crystalline form of 2-n-butyl-3-((2-(1h-tetrazole-5-yl) (1,1'-biphenyl)-4-methyl)-1,3-diazapspiro (4,4') non -1- en-4-one |
| EP1918288A1 (en) | 2006-11-02 | 2008-05-07 | Cadila Pharmaceuticals Limited | A novel and improved process for the preparation of Irbesartan, an angiotensin-II receptor antagonist for the treatment of hypertension |
| PL2065035T3 (pl) * | 2007-11-28 | 2011-02-28 | Lesvi Laboratorios Sl | Preparaty farmaceutyczne zawierające irbesartan |
| WO2009072137A2 (en) * | 2007-12-07 | 2009-06-11 | Hetero Drugs Limited | Process for pure irbesartan |
| KR101009383B1 (ko) * | 2008-04-30 | 2011-01-19 | 켐젠주식회사 | 고순도의2-부틸-3-[[2'-(1에이취-테트라졸-5-일)[1,1'-비페닐]-4-일]메틸]-1,3-디아자스피로[4.4]논-1-엔-4-온 화합물의제조방법 |
| EP2417110B1 (en) * | 2009-04-08 | 2014-05-07 | CTX Life Sciences Pvt. Ltd. | A one pot process for preparing 2-butyl-3-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro [4, 4]non-1-en-4-one (irbesartan) |
| AR078107A1 (es) * | 2009-08-31 | 2011-10-12 | Sanofi Aventis | Uso de irbesartan para la preparacion de un medicamento para la prevencion de la hospitalizacion por insuficiencia cardiaca |
| US8080670B2 (en) | 2010-05-04 | 2011-12-20 | Divi's Laboratories, Ltd. | Process for the preparation of irbesartan |
| FR2977253B1 (fr) | 2011-06-30 | 2013-08-09 | Centre Nat Rech Scient | Reactif organostannique alcoxyle supporte, preparation et utilisation pour la synthese de tetrazoles en phase heterogene |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
| US11655220B2 (en) | 2020-10-22 | 2023-05-23 | Hetero Labs Limited | Process for the preparation of angiotensin II receptor blockers |
| CN118556049A (zh) | 2021-10-01 | 2024-08-27 | 赛诺菲 | 用于制备具有四唑环的沙坦活性化合物的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE70593B1 (en) * | 1989-09-29 | 1996-12-11 | Eisai Co Ltd | Biphenylmethane derivative the use of it and pharmacological compositions containing same |
| JP2697919B2 (ja) * | 1989-09-29 | 1998-01-19 | キヤノン株式会社 | 信号内挿回路及び該回路を備えた変位測定装置 |
| US5104891A (en) * | 1989-12-11 | 1992-04-14 | G. D. Searle & Co. | Cycloheptimidazolone compounds as angiotensin ii antagonists for control of hypertension |
| TW201738B (cs) * | 1990-03-20 | 1993-03-11 | Sanofi Co | |
| IL99372A0 (en) * | 1990-09-10 | 1992-08-18 | Ciba Geigy Ag | Azacyclic compounds |
| FR2673427B1 (fr) * | 1991-03-01 | 1993-06-18 | Sanofi Elf | Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant. |
-
1994
- 1994-10-19 FR FR9412459A patent/FR2725987B1/fr not_active Expired - Fee Related
-
1995
- 1995-10-17 US US08/544,027 patent/US5629331A/en not_active Expired - Lifetime
- 1995-10-17 CA CA002160725A patent/CA2160725C/en not_active Expired - Fee Related
- 1995-10-17 CZ CZ19952710A patent/CZ288629B6/cs not_active IP Right Cessation
- 1995-10-18 SI SI9530469T patent/SI0708103T1/xx unknown
- 1995-10-18 PT PT95402322T patent/PT708103E/pt unknown
- 1995-10-18 NO NO954154A patent/NO307516B1/no not_active IP Right Cessation
- 1995-10-18 EP EP95402322A patent/EP0708103B1/fr not_active Expired - Lifetime
- 1995-10-18 RU RU95118109/04A patent/RU2144536C1/ru active
- 1995-10-18 CN CN95118711A patent/CN1061656C/zh not_active Expired - Lifetime
- 1995-10-18 ES ES95402322T patent/ES2155115T3/es not_active Expired - Lifetime
- 1995-10-18 DE DE69519788T patent/DE69519788T2/de not_active Expired - Lifetime
- 1995-10-18 AT AT95402322T patent/ATE198478T1/de active
- 1995-10-18 DK DK95402322T patent/DK0708103T3/da active
- 1995-10-18 PL PL95311012A patent/PL184193B1/pl not_active IP Right Cessation
- 1995-10-18 TW TW084110953A patent/TW357147B/zh not_active IP Right Cessation
- 1995-10-19 ZA ZA958850A patent/ZA958850B/xx unknown
- 1995-10-19 JP JP27151295A patent/JP3366786B2/ja not_active Expired - Lifetime
- 1995-10-19 HU HU9503016A patent/HU226461B1/hu unknown
- 1995-10-19 AU AU34335/95A patent/AU698041B2/en not_active Ceased
- 1995-10-19 FI FI954992A patent/FI114156B/fi not_active IP Right Cessation
- 1995-10-19 KR KR1019950036285A patent/KR100251222B1/ko not_active Expired - Fee Related
- 1995-10-19 NZ NZ280293A patent/NZ280293A/en not_active IP Right Cessation
- 1995-10-19 IL IL11568895A patent/IL115688A/xx not_active IP Right Cessation
-
2000
- 2000-07-07 CZ CZ20002544A patent/CZ288624B6/cs not_active IP Right Cessation
-
2001
- 2001-03-05 GR GR20010400343T patent/GR3035503T3/el unknown
-
2002
- 2002-05-15 CY CY0200030A patent/CY2277B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI114156B (fi) | Menetelmä tetratsolijohdannaisen valmistamiseksi kahtena kidemuotona ja mainitun johdannaisen uusi kidemuoto | |
| US8592474B2 (en) | Process for the preparation or purification of olmesartan medoxomil | |
| WO2002094816A1 (en) | Process for the crystallization of losartan potassium | |
| EP1590343B1 (en) | Synthesis of 2-butyl-3-(2' -(1-trityl-1h-tetrazol-5-yl)biphen yl-4-yl)-1,3-diazaspiro-4,4 -nonene-4-one | |
| JP2004520446A5 (cs) | ||
| EP1912956B1 (en) | Metal salts of 2'-(1h-tetraz0l-5-yl) -1,1'-biphenyl-4-carboxaldehyde | |
| US20080214637A1 (en) | Process for the Synthesis of Tetrazoles | |
| EP1773818B1 (en) | Preparation of hydrochloride salts of tetrazole derivative | |
| WO2007003280A1 (en) | A process for the preparation of losartan derivatives by chlorination and reduction of the respective 1h-imidazole-5-carbaldehydes | |
| WO2006001026A1 (en) | Irbesartan polymorphs | |
| EP2022790A1 (en) | A process for the preparation or purification of olmesartan medoxomil | |
| HK1005135B (en) | Process for the preparation of a tetrazole derivative in two crystalline forms and a new crystalline form of this derivative | |
| WO2008041957A1 (en) | Method for producing pure crystalline form of 2-n-butyl-3-((2-(1h-tetrazole-5-yl) (1,1'-biphenyl)-4-methyl)-1,3-diazapspiro (4,4') non -1- en-4-one | |
| HK1135379A (en) | Metal salts of 2'-(1h-tetraz0l-5-yl)-1.1'-biphenyl-4-carboxaldehyde |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Transfer of assignment of patent |
Owner name: SANOFI-AVENTIS |
|
| MM | Patent lapsed |